ReviewHeart failure reviews2009
Role of guanylate cyclase modulators in decompensated heart failure.
Review in Heart failure reviews, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- Sacubitril/valsartan, sodium-glucose cotransporter 2 inhibitors and vericiguat for congestive heart failure therapy.Basic & clinical pharmacology & toxicology · 2022Pooled it
- Vericiguat in worsening heart failure: agonising over, or celebrating, agonism in the VICTORIA trial.Cardiovascular research · 2020Article
- Soluble Guanylate Cyclase Stimulators and Activators: Novel Therapies for Pulmonary Vascular Disease or a Different Method of Increasing cGMP?Current hypertension reports · 2016Review
- Systems Pharmacology and Rational Polypharmacy: Nitric Oxide-Cyclic GMP Signaling Pathway as an Illustrative Example and Derivation of the General Case.PLoS computational biology · 2016Article
- Ularitide for the treatment of acute decompensated heart failure: from preclinical to clinical studies.European heart journal · 2015Review
- Insights into soluble guanylyl cyclase activation derived from improved heme-mimetics.Journal of medicinal chemistry · 2013Article
- Novel vasodilators in heart failure.Current heart failure reports · 2013Review
- Can we prevent or treat renal dysfunction in acute heart failure?Heart failure reviews · 2012Review
- Renal dysfunction in acute heart failure: epidemiology, mechanisms and assessment.Heart failure reviews · 2012Review
- Natriuretic peptides in therapy for decompensated heart failure.European journal of clinical pharmacology · 2012Review
- cGMP Signaling, Phosphodiesterases and Major Depressive Disorder.Current neuropharmacology · 2011Article
- Novel therapeutic targets for the treatment of heart failure.Nature reviews. Drug discovery · 2011Review
- Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease.Circulation · 2011Review
- Update on the Management of Acute Decompensated Heart Failure.Current treatment options in cardiovascular medicine · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this review we investigate the role of particulate and soluble guanylate cyclase (pGC and sGC, respectively) pathways in heart failure, and several novel drugs that modify guanylate cyclase. Nesiritide and ularitide/urodilatin are natriuretic peptides with vasodilating, natriuretic and diuretic effects, acting on pGC, whilst cinaciguat (BAY 58-2667) is a novel sGC activator. Cinaciguat has a promising and novel mode of action because it can stimulate cyclic guanosine-3',5'-monophosphate synthesis by targeting sGC in its nitric oxide-insensitive, oxidised ferric (Fe(3+)) or haem-free state. Thus, cinaciguat may also be effective under oxidative stress conditions resulting in oxidised or haem-free sGC refractory to traditional organic nitrate therapies. Preliminary studies of cinaciguat in patients with acute decompensated heart failure show substantial improvements in haemodynamics and symptoms, whilst maintaining renal function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.